Radiation safety management for stereotactic body radiation therapy incidentally concurrent with Pluvicto® (Lu-177)...

A patient with castration-resistant prostate cancer (CRPC) was referred to our clinic seeking palliative management of a painful metastasis in the left pelvis. At the time of referral, the patient was receiving [177Lu]Lu-PSMA 617 (Pluvicto®) therapy at an outside institution, with the next scheduled administration approaching within days. As the patient's next Pluvicto® cycle could coincide with the planned SBRT, the radiation oncologist consulted with the medical health physics team to evaluate potential radiation safety concerns and to determine an appropriate treatment timeline. This case report details the radiation safety considerations, dose estimations, and the measured dose rate readings on the patient to balance the optimal patient care and to minimize staff exposure.